Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Change in Account Payables (2021 - 2024)

Opus Genetics (IRD) has disclosed Change in Account Payables for 3 consecutive years, with $373000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Change in Account Payables rose 195.64% to $373000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $1.1 million, a 310.1% increase, with the full-year FY2024 number at $220000.0, down 79.67% from a year prior.
  • Change in Account Payables was $373000.0 for Q4 2023 at Opus Genetics, up from -$545000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.2 million in Q1 2023 to a low of -$545000.0 in Q3 2023.
  • A 3-year average of $79000.0 and a median of $78500.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 876.36% in 2022, then surged 23140.0% in 2023.
  • Opus Genetics' Change in Account Payables stood at $165000.0 in 2021, then plummeted by 336.36% to -$390000.0 in 2022, then surged by 195.64% to $373000.0 in 2023.
  • Per Business Quant, the three most recent readings for IRD's Change in Account Payables are $373000.0 (Q4 2023), -$545000.0 (Q3 2023), and $102000.0 (Q2 2023).